This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Resources

Quick Hits Resources

Navigating Treatment Emergent Adverse Events (TEAEs) in Prostate Cancer Therapy

Prostate Cancer Banner

Welcome to our Quick Hits Resources section, where we focus on the critical topic of treatment emergent adverse events (TEAEs) associated with androgen receptor inhibitors (ARIs) in prostate cancer treatment. Understanding the potential adverse events linked to each treatment is essential for optimising patient care and ensuring the best possible outcomes.

Prioritising the quality of life for patients is fundamental in treatment decision-making. TEAEs can lead to treatment discontinuation, increased healthcare costs, and a negative impact on patient well-being. Therefore, it is vital for healthcare professionals to be aware of these events to make informed choices that enhance patient care.

 

In this section, we are sharing three informative infographics that highlight key TEAEs associated with ARIs, specifically focusing on rash, fatigue, and cardiovascular issues.

These resources provide valuable insights into how these adverse events can affect patients and the importance of managing them effectively.

Explore the infographics below to gain a deeper understanding of the implications of TEAEs in prostate cancer treatment and discover strategies to improve patient quality of life.

 

For full information on adverse events for NUBEQA, please consult the Summary of Product Characteristics.

Quick Hits Resources_Cardiovascular

Cardiovascular

DDI

Drug-Drug Interactions

PP-NUB-GB-2231 | March 2025


    • 1
      NUBEQA (darolutamide) Summary of Product Characteristics.